In vivo最新文献

{"title":"Effect of DNA Aptamer Concentration on the Stability of PDA Nanoparticle-based Electrochemical Biosensor to Detect Glycated Albumin.","authors":"Ohnmar Zaw, Nang Noon Shean Aye, Paweena Tunakhun, Jureerut Daduang, Sakda Daduang, Pornsuda Maraming","doi":"10.21873/invivo.13945","DOIUrl":"https://doi.org/10.21873/invivo.13945","url":null,"abstract":"<p><strong>Background/aim: </strong>The glycated albumin (GA), a potential biomarker for monitoring diabetes mellitus, reflects short-term glycemia and is not influenced by conditions that falsely alter hemoglobin A1c (HbA1c) levels. This study presents a comprehensive evaluation of DNA aptamer-functionalized polydopamine nanoparticles (PDA NPs) for developing a stable biosensor targeting GA.</p><p><strong>Materials and methods: </strong>DNA aptamers, conjugated to PDA NPs at varying aptamer concentrations (0.05, 0.5, and 5 μM), were systematically analyzed to understand their impact on the morphological, electrochemical behavior, and stable responses of the biosensor.</p><p><strong>Results: </strong>Morphological assessments using transmission electron microscopy, scanning electron microscopy, and atomic force microscopy confirmed the stability of PDA NPs after conjugation with aptamers. Electrochemical characterization demonstrated enhanced electron transfer efficiency at an optimal aptamer concentration (0.5 μM) for GA detection while stability testing over 30 days indicated sustained sensor functionality.</p><p><strong>Conclusion: </strong>The PDA-0.5 μM aptamer conjugations balance structural integrity, and stability, emphasizing the importance of aptamer concentration optimization for practical biosensor applications.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1440-1452"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibitory Effect of Clopidogrel, a P2Y₁₂ Receptor Antagonist, on Hematogenic Metastasis in B16-BL6 Mouse Melanoma Cells.","authors":"Noriko Yoshikawa, Mingyu Xia, Kazuki Nakamura","doi":"10.21873/invivo.13936","DOIUrl":"https://doi.org/10.21873/invivo.13936","url":null,"abstract":"<p><strong>Background/aim: </strong>The complex interactions between circulating platelets and tumor cells play important roles in tumor metastasis. Tumor cells can activate platelets by releasing mediators such as adenosine diphosphate (ADP). Treatments with anticoagulants have been shown to attenuate tumor metastasis. However, the role of ADP receptor P2Y₁₂ in tumor cell metastasis has not been fully clarified.</p><p><strong>Materials and methods: </strong>In this study, highly metastatic B16-BL6 mouse melanoma cells were injected into the tail vein of mice as a model of hematogenic tumor metastasis to investigate the effects of P2Y₁₂ antagonist clopidogrel on tumor metastasis.</p><p><strong>Results: </strong>A high dose (25 mg/kg) of clopidogrel weakly but significantly inhibited lung metastasis and increased both the time to hemostasis and blood loss in the tail tip-excision mouse model.</p><p><strong>Conclusion: </strong>Although it is necessary to consider increased bleeding as a side-effect, clopidogrel may be an effective antimetastatic drug.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1325-1330"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin.","authors":"Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, Takafumi Minami, Takafumi Yanagisawa, Wataru Fukuokaya, Ryoichi Maenosono, Yuki Yoshikawa, Takuya Tsujino, Masanobu Saruta, Kiyoshi Takahara, Yosuke Hirasawa, Takeshi Hashimoto, Yoshio Ohno, Takahiro Kimura, Ryoichi Shiroki, Kazutoshi Fujita","doi":"10.21873/invivo.13953","DOIUrl":"https://doi.org/10.21873/invivo.13953","url":null,"abstract":"<p><strong>Background/aim: </strong>Cancer-induced pain (CIP) exacerbates patient's quality of life. However, it is unknown whether CIP is associated with survival in urothelial carcinoma (UC) patients treated with enfortumab vedotin (EV). This study retrospectively investigated the prognostic significance of CIP in EV-treated UC patients.</p><p><strong>Patients and methods: </strong>We analyzed clinical data from patients with locally advanced or metastatic UC who received EV treatment, assessing various factors such as age, metastasis site, ECOG Performance Status (PS), and CIP status prior to treatment. CIP was determined based on clinical records cancer-related pain or the use of analgesics for pain management.</p><p><strong>Results: </strong>A total of 114 patients (78 males and 36 females) were included in the study. The group with CIP included significantly higher number of patients with bone metastasis. Progression-free survival of the patients with CIP was not significantly different from those without CIP. However, the patients with CIP showed worse overall survival (OS) than those without CIP. Cox proportional regression analysis showed that CIP, liver metastasis, and ECOG PS were significant predictors of poorer OS.</p><p><strong>Conclusion: </strong>CIP before the treatment of EV was a significant predictor of reduced OS in patients with UC. Early management of CIP or initiation of EV therapy before CIP development may improve survival outcomes.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1533-1539"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance <i>In Vitro</i> Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice.","authors":"Sei Morinaga, Kohei Mizuta, Byung Mo Kang, Qinghong Han, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Hiroyuki Tsuchiya, Satoru Demura, Robert M Hoffman","doi":"10.21873/invivo.13931","DOIUrl":"https://doi.org/10.21873/invivo.13931","url":null,"abstract":"<p><strong>Background/aim: </strong>Eribulin is a microtubule inhibitor used in the treatment of various malignancies, including soft-tissue sarcoma. However, the development of eribulin resistance is a recalcitrant clinical problem. The present study demonstrates that super eribulin-resistant HT1080 human fibrosarcoma cells become highly malignant but can be eradicated synergistically by the combination of eribulin and methionine restriction in nude mice.</p><p><strong>Materials and methods: </strong>The cell viability of parental HT1080 cells and super eribulin-resistant HT1080 was determined following eribulin treatment using the WST-8 reagent. <i>In vitro</i> invasion assays, comprising wound-healing of cell monolayers, were performed to determine the degree of malignancy. Tumor growth to determine malignancy and tumor-growth sensitivity to eribulin, or a methionine-restricted diet, or their combination were analyzed in athymic nude mice.</p><p><strong>Results: </strong>The IC₅₀ of eribulin for parental HT1080 cells was 0.15 nM, whereas for super eribulin-resistant HT1080 cells, the IC₅₀ of eribulin was 18 nM, a 120-fold increase. Super eribulin-resistant HT1080 cells had a more rapid wound-healing closure rate <i>in vitro</i> than their parental HT1080 cells, indicating increased malignancy. Similarly, <i>in vivo</i>, untreated super eribulin-resistant HT1080 tumors grew faster than parental HT1080 tumors, confirming their high malignancy. The combination of a methionine-restricted diet and eribulin synergistically arrested super eribulin-resistant HT1080 tumors. Methionine restriction sensitized these highly resistant and malignant cells to eribulin.</p><p><strong>Conclusion: </strong>Methionine restriction combined with eribulin represents a promising strategy to effectively treat eribulin-resistant high-malignancy fibrosarcoma, that can be immediately applied to the clinic.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1275-1282"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Role of Prostate-specific Antigen Isoforms and Their Early Kinetics in Patients With Metastatic Castration-resistant Prostate Cancer Receiving New Generation Androgen Receptor Targeted Agents.","authors":"Ondřej Fiala, Petr Hošek, Hana Korunková, Michaela Tkadlecová, Milan Hora, Dominika Šiková, Petr Stránský, Jindřich Fínek, Radek Kučera, Jindra Windrichová, Ondřej Topolčan","doi":"10.21873/invivo.13889","DOIUrl":"10.21873/invivo.13889","url":null,"abstract":"<p><strong>Background/aim: </strong>New generation androgen receptor-targeting agents (ARTA) have been in the spotlight for their efficacy in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific antigen (PSA) represents one of the most commonly used serum cancer biomarkers worldwide. The present retrospective study focused on the prognostic role of serum PSA isoforms and their early dynamics in mCRPC patients treated with abiraterone acetate (ABI) or enzalutamide (ENZ).</p><p><strong>Patients and methods: </strong>The association between outcomes of 334 mCRPC patients treated with ABI or ENZ and the levels of serum total PSA (tPSA), free PSA (fPSA), [-2]proPSA and the Prostate Health Index (PHI) at baseline and one month after treatment initiation was analyzed retrospectively.</p><p><strong>Results: </strong>In the multivariable Cox proportional hazards models, baseline tPSA>50 μg/l (<i>p</i><0.001), and [-2]proPSA>300 ng/l (<i>p</i>=0.017) remained independent significant factors associated with inferior OS, while baseline fPSA>1.75 μg/l (<i>p</i>=0.050) and Δ [-2]proPSA >-50% approached statistical significance (<i>p</i>=0.062). The results of ROC analyses assessing the ability of baseline tPSA, fPSA, and [-2]proPSA to predict mortality within two years showed area under the curve (AUC) values of 0.709, 0.685, and 0.740, respectively. Among the subgroup with baseline tPSA≤20.0 μg/l, the results of ROC analyses for baseline tPSA, fPSA and [-2]proPSA showed AUC values of 0.441, 0.682, and 0.688, respectively.</p><p><strong>Conclusion: </strong>Our results suggest a significant correlation between pretreatment serum levels of tPSA and [-2]proPSA with OS in mCRPC patients receiving ARTA.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"859-869"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alteration of Apparent Diffusion Coefficient Measurements Predict Survival Outcomes During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.","authors":"Yuma Wada, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Mitsuo Shimada","doi":"10.21873/invivo.13897","DOIUrl":"10.21873/invivo.13897","url":null,"abstract":"<p><strong>Background/aim: </strong>Neoadjuvant chemoradiation therapy (nCRT) followed by surgery is recommended for patients with locally advanced rectal cancer (LARC). However, because 30%-40% of patients with LARC do not respond to nCRT, better prediction of treatment responses and survival outcomes is required. Therefore, this study aimed to identify apparent diffusion coefficient (ADC) values that predict survival outcomes after nCRT in patients with LARC.</p><p><strong>Patients and methods: </strong>We analyzed data from 66 patients with LARC who underwent nCRT and evaluated the ADC values pre- and post-nCRT. Cox proportional hazard regression analyses were conducted to assess survival outcomes.</p><p><strong>Results: </strong>There were no significant differences in disease-free survival (DFS) and overall survival (OS) between low and high ADC values pre-nCRT. However, patients classified as low ADC in post-nCRT had a significantly worse prognosis in OS and DFS (OS: <i>p</i>=0.01; DFS: <i>p</i><0.01) than patients classified as high ADC. Moreover, an alteration in ADC values between pre- and post-nCRT was associated with poor OS [univariate, <i>p</i><0.01; multivariate: <i>p</i>=0.01]. Finally, we identified ADC values that were significantly superior in predicting tumor regression grade, demonstrating remarkable diagnostic accuracy [post-nCRT: area under the curve (AUC)=0.79; alteration-nCRT: AUC=0.85].</p><p><strong>Conclusion: </strong>We identified the clinical importance of changes in ADC values as a predictor of survival outcomes in patients with LARC. These results highlight the clinical importance of ADC values on improving the treatment strategies of patients.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"927-935"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Dosimetric Comparison of HyperArc Therapy Planning and Volumetric Modulated Arc Therapy Planning in Treating Patients With Glioblastoma Multiforme.","authors":"Wei-Ju Hong, Hsiu-Wen Ho, Hsiu-Man Lin, Tung Lin, Wan-Hsuan Chow, Ching-Chieh Yang, Li-Ching Lin","doi":"10.21873/invivo.13906","DOIUrl":"10.21873/invivo.13906","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed at evaluating the potential benefit of automatic non-coplanar volumetric arc therapy (VMAT) (hyperarc, HA) technique in treating glioblastoma multiforme (GBM).</p><p><strong>Patients and methods: </strong>Twenty-seven patients with GBM who received coplanar VMAT (C-VMAT) were selected in this study. HA and non-coplanar VMAT (NC-VMAT) plans were generated with the same prescriptions and constraints. The Target coverage, organs at risk (OARs) dose, and dosimetric indexes were compared among three plans.</p><p><strong>Results: </strong>The HA plan demonstrated a reduction in dose to normal tissues while maintaining target coverage, compared to C-VMAT and NC-VMAT. Additionally, HA plans demonstrated higher coverage of the GTV and PTV₆₀ as well as improved CI from PTV₆₀ and PTV₄₆ compared to the other plans. Regarding the dose gradient, HA plans showed a greater dose fall-off, resulting in reduced high-dose and intermediate-dose spillage at PTV₄₆ The HA also demonstrated a tighter gradient radius at PTV₆₀ and PTV₄₆ The HA plan requires fewer MUs than both C-VMAT and NC-VMAT.</p><p><strong>Conclusion: </strong>The HA plan had better dosimetric results compared to C-VMAT and NC-VMAT. The HA with automatic planning module and auto-delivery treatment also provided high-quality planning and delivery efficacy. These advantages suggest that HA could potentially escalate tumor doses while minimizing toxicity, thereby improving outcomes in GBM patients.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1009-1021"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal Expression Levels of C5a Receptor and Autophagy-related Beclin-1 and LC3A/B Are Simultaneously Enhanced Under Immunoglobulin Treatment in a Rat Model of Sepsis.","authors":"Özlem Polat, Gunseli Orhun, Ilkay Anakli, Vuslat Yilmaz, Gizem Koral, Canan Ulusoy, Mert Canbaz, Perihan Ergin Ozcan, Erdem Tüzün, Figen Esen","doi":"10.21873/invivo.13883","DOIUrl":"10.21873/invivo.13883","url":null,"abstract":"<p><strong>Background/aim: </strong>Sepsis-induced acute kidney injury is a fatal, potentially reversible clinical condition. C5a receptor (C5aR) has been implied to play pivotal roles in both autophagy and sepsis-induced organ dysfunction. The aim of this study was to demonstrate the effects of intravenous immunoglobulin preparations on the expression of autophagy markers and investigate possible association between C5aR expression and autophagy in the kidney tissue of septic rats.</p><p><strong>Materials and methods: </strong>Sepsis was induced by cecal ligation perforation (CLP) in rats, which were divided into control, sham, CLP+saline, CLP+IgG (250 mg/kg, <i>iv</i>), and CLP+immunoglobulins enriched with immunoglobulin M (IgGAM) (250 mg/kg, <i>iv</i>) groups. Kidney samples were obtained in two sets of experiments to examine the early (1 day) and late (10 days) effects of treatment. Renal expression levels of C5aR, LC3A/B, and beclin-1 were measured using immunoblotting.</p><p><strong>Results: </strong>CLP did not enhance the renal expression of autophagy markers or C5aR. Contrariwise, IgG, and IgGAM administration reduced mortality caused by the CLP procedure and significantly increased C5aR, beclin-1, and LC3A/B expression levels in kidney samples of septic rats. Surviving rats had higher renal expression levels of C5aR, beclin-1, and LC3A/B than deceased rats. Expression levels of C5aR, beclin-1, and LC3A/B showed a strong correlation during the early stage of CLP-induced sepsis but not in the late stage.</p><p><strong>Conclusion: </strong>Human-derived immunoglobulin preparations may ameliorate sepsis-related organ dysfunction partially through autophagy-related mechanisms. In the early stage of treatment, enhancement of autophagy in the kidney appears to be associated with C5aR expression.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"810-818"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors of Developing Leptomeningeal Seeding After Resection of Brain Metastasis in Patients With Breast Cancer: Defining the Indication for Preoperative SRS.","authors":"Ji Hyun Hong, Jieun Lee, Kabsoo Shin, Byung-Ock Choi, Jae Sung Park, Stephen Ahn, Jin-Ho Song","doi":"10.21873/invivo.13914","DOIUrl":"10.21873/invivo.13914","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to identify the incidence and risk factors for leptomeningeal seeding (LMS) in patients with breast cancer following brain metastasis resection and radiotherapy (RT) and to determine potential candidates for preoperative stereotactic radiosurgery (SRS).</p><p><strong>Patients and methods: </strong>Between 2012 and 2022, 33 patients with breast cancer underwent surgical resection and postoperative RT for newly detected brain metastases. Twenty-one patients received whole-brain RT, while 12 patients were treated with SRS. Survival and incidence of LMS development were retrospectively analyzed. Several risk factors for the development of LMS were identified.</p><p><strong>Results: </strong>After a median follow-up of 25.3 months, the 1- and 3-year overall survival (OS) rates were 81.2% and 58.1%, respectively. Development of LMS was the only significant factor affecting OS in multivariate analysis (Hazard ratio=3.08). Significant risk factors for LMS included age ≤45 years, triple-negative breast cancer (TNBC), and piecemeal resection. The 1-year LMS risk was 85.7% for younger patients, 46.2% for those with TNBC or piecemeal resection, and 11.1% for older patients without TNBC undergoing en-bloc resection.</p><p><strong>Conclusion: </strong>Patients with breast cancer brain metastases who were ≤45 years old, had TNBC, or underwent piecemeal resection were at high risk of developing LMS, regardless of the postoperative RT technique used. Patients with these risk factors are essential candidates for alternative treatment approaches, such as preoperative SRS.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1094-1103"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy.","authors":"Minehiko Inomata, Daisuke Furukawa, Naoki Takata, Kotaro Tokui, Seisuke Okazawa, Shingo Imanishi, Satoshi Nomura","doi":"10.21873/invivo.13925","DOIUrl":"10.21873/invivo.13925","url":null,"abstract":"<p><strong>Background/aim: </strong>There is insufficient evidence regarding the optimal treatment for squamous cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, and a standard treatment strategy has not been established.</p><p><strong>Case report: </strong>A 60-year-old woman was diagnosed with advanced EGFR-mutant squamous cell lung cancer. She was treated with EGFR tyrosine kinase inhibitors and then received the combined therapy of cytotoxic agents plus immune checkpoint inhibitors as third-line therapy. She was then treated with the fourth-line combination therapy of cisplatin, gemcitabine, and necitumumab, which resulted in a progression-free survival of 5.0 months and shrinkage of the liver metastatic lesion.</p><p><strong>Conclusion: </strong>The combination therapy of cisplatin, gemcitabine, and necitumumab was effective in treating pretreated EGFR-mutant squamous cell lung cancer in this case. It is necessary to accumulate more evidence to determine the most effective treatment for advanced EGFR-mutant squamous cell lung cancer.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1207-1210"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}